Targeted Genetics Phase II cancer data

TGEN released Phase II data of its 24-patient trial with tgDCC-E1A to treat recurrent head and neck squamous cell carcinoma. Of 20 evaluable patients, 9 had stabilization of disease and 1 had a comple...